Abbott Laboratories 2013 Annual Report Download - page 40

Download and view the complete annual report

Please find page 40 of the 2013 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

ABBOTT 2013 ANNUAL REPORT
38
Year Ended December 31 2013 2012 2011
Common Shares:
Beginning of Year
Shares: 2013: 1,675,930,484; 2012: 1,638,870,201; 2011: 1,619,689,876 $ 11,755 $  9,817 $ 8,745
Issued under incentive stock programs
Shares: 2013: 9,896,612; 2012: 37,060,283; 2011: 19,180,325 393 1,854 954
Share‑based compensation 261 435 382
Issuance of restricted stock awards (361) (351) (264)
End of Year
Shares: 2013: 1,685,827,096; 2012: 1,675,930,484; 2011: 1,638,870,201 $12,048 $ 11,755 $  9,817
Common Shares Held in Treasury:
Beginning of Year
Shares: 2013: 99,262,992; 2012: 68,491,382; 2011: 72,705,928 $ (5,591) $ (3,688) $ (3,917)
Issued under incentive stock programs
Shares: 2013: 5,718,575; 2012: 6,691,748; 2011: 4,638,841 310 363 250
Purchased
Shares: 2013: 44,184,393; 2012: 37,463,358; 2011: 424,295 (1,563) (2,266) (21)
End of Year
Shares: 2013: 137,728,810; 2012: 99,262,992; 2011: 68,491,382 $(6,844) $ (5,591) $ (3,688)
Earnings Employed in the Business:
Beginning of Year $ 24,151 $20,907 $ 19,216
Net earnings 2,576 5,963 4,728
Separation of AbbVie Inc. (3,735) — —
Cash dividends declared on common shares
(per share — 2013: $0.64; 2012: $1.67; 2011: $1.92) (1,002) (2,650) (3,012)
Effect of common and treasury share transactions (11) (69) (25)
End of Year $21,979 $ 24,151 $20,907
Accumulated Other Comprehensive Income (Loss):
Beginning of Year $ (3,594) $ (2,597) $ (1,367)
Separation of AbbVie Inc. 1,010 — —
Other comprehensive income (loss) 572 (997) (1,230)
End of Year $ (2,012) $ (3,594) $ (2,597)
Noncontrolling Interests in Subsidiaries:
Beginning of Year $    92 $     86 $    88
Noncontrolling Interests’ share of income,
business combinations, net of distributions and share repurchases 4 6 (2)
End of Year $    96 $     92 $    86
The accompanying notes to consolidated financial statements are an integral part of this statement.
CONSOLIDATED STATEMENT OF SHAREHOLDERS’ INVESTMENT
(in millions except shares and per share data)